[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Aromatase inhibitors (AIs) are a class of drugs that block the aromatase enzyme, which is responsible for converting androgens (male hormones) into estrogens (female hormones). These medications ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Prescribing drugs "off-label" means that a healthcare provider has prescribed a medication ... One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone ...

The FDA also expanded the indication for metastatic disease: abemaciclib can now be used in combination with an aromatase inhibitor for the treatment of people with HR+, HER2- advanced or metastatic ...

This is a new kind of oral selective estrogen receptor degrader (SERD), used to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

when the SMC gave the green light for restricted prescribing of the drug in first-line HR+/HER2- breast cancer in combination with aromatase inhibitor drugs. Both are also trying to get the okay ...

There were more grade 3/4 drug-related adverse events, however, coming in at 18.9% in the combination arm compared to 9.7% with Opdivo, and discontinuation rates were 14.6% and 6.7%, respectively.

They describe the strength of evidence as compelling, highlighting the therapeutic potential of maintaining CDK4/6 inhibitor treatment when combating drug-resistant breast cancer. They also highlight ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...